News

Novartis announced that the European Commission (EC) has approved Adakveo (crizanlizumab) for the prevention of recurrent vaso-occlusive crises (VOCs), or pain crises, in patients with…
Read More...

Protagonist Therapeutics, Inc. announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, confirmed that the…
Read More...

AbCellera and Kodiak Sciences Inc. announced a new partnership to generate therapeutic antibody candidates in ophthalmology. Following a previously successful collaboration, AbCellera…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients…
Read More...

Eli Lilly and Company announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for…
Read More...

Novartis and Molecular Partners AG announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19…
Read More...

CStone Pharmaceuticals announced a licensing agreement with LegoChem Biosciences, Inc. for the development and commercialization of LCB71, a potential first-in-class/best-in-class…
Read More...

Releviate Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from chronic pain, signs an exclusive license for two patent pending human monoclonal…
Read More...

insitro, a machine-learning driven drug discovery and development company, today announced that it has entered into a five-year, discovery collaboration with Bristol Myers Squibb (NYSE:…
Read More...

Sanofi and GSK have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable…
Read More...

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy,…
Read More...

Kala Pharmaceuticals, Inc. a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye announced that the…
Read More...

Histogen Inc. a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy…
Read More...

SFJ Pharmaceuticals is pleased to note that its partner Apellis Pharmaceuticals Inc. and Swedish Orphan Biovitrum AB announced a strategic collaboration to accelerate the advancement of…
Read More...

HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced the successful completion of the first…
Read More...

Knight Therapeutics Inc. a leading pan-American (ex-US) specialty pharmaceutical company, announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. for…
Read More...

Bayer AG announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing…
Read More...

ANA Therapeutics announced that it has begun a multicenter, Phase 2/3 clinical trial to evaluate the safety and efficacy of its proprietary, oral niclosamide (ANA001) formulation for…
Read More...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a supply…
Read More...